<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

Neuro Therapies

Spotlight on Medtronic Neuromodulation: NANS 2023

Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodu...

Neuro Therapies

Emerging Technologies in Neurointervention

SmartTRAK identifies emerging technologies at the most recent SNIS and ESMINT meetings that have the pot...

Neuro Therapies

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-env...

Neuro Therapies

SNIS 2022: Advancing Stroke Research and Innovation

SNIS President Michael Chen, MD discusses advancing stroke research and innovation in an interview with ...

Neuro Therapies

Acandis Inc: Targeting the US Market for Neurointervention

Georg Schauer, PhD, President of Acandis Inc., discusses the Company, its novel devices and targeting th...

Neuro Therapies

R92 Medical: Reimagining the Road to Stroke Interventions

Adam Hattan, VP of Marketing for Route 92 Medical, discusses the Company, its novel system for mechanica...

Neuro Therapies

Partnering for Success in Neurovascular: Wallaby Medical

Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH ...

Neuro Therapies

STIMVIEW XT: A New Approach to DBS Programming

Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Com...

Neuro Therapies

A Bumpy Ride: Q122 Spinal Cord Stimulation Market Recap

Q122 SCS Market revenues were up in the low-single digit YoY, but pandemic-related issues made it a bump...

Neuro Therapies

Opportunities in Neuromodulation: Abbott at INS 2022

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with Smart...

1 2 3 4 5
...
12